ClinicalTrials.Veeva

Menu
MedTraits NY | New York, NY logo

MedTraits NY | New York, NY

Research site

Site insights

Top conditions

Top treatments

Duvakitug
MZE829
Tozorakimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

7 of 7 total trials

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease (STARSCAPE-2)

This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in p...

Enrolling
Crohn's Disease
Drug: Duvakitug
Drug: Placebo

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in par...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Duvakitug

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Enrolling
Proteinuric Kidney Disease
Drug: MZE829

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate...

Enrolling
Crohn's Disease
Drug: Duvakitug
Drug: Placebo

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of du...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Duvakitug

The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.Changes will...

Active, not recruiting
Asthma
Biological: Benralizumab
Biological: Placebo

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered su...

Enrolling
Asthma
Drug: Placebo
Drug: Tozorakimab

Trial sponsors

Sanofi logo
AstraZeneca logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems